



ASX ANNOUNCEMENT

Results of Share Purchase Plan

MELBOURNE, Australia (1 May 2026) – Lumos Diagnostics Holdings Limited (ASX: LDX, “Lumos” or the “Company”), is pleased to announce the results of its non-underwritten Share Purchase Plan (“SPP”) which closed on 24 April 2026. The SPP complements Lumos’ successful non-underwritten A\$20 million placement to new and existing institutional investors announced on 27 March 2026 (“Placement”).

Doug Ward, CEO of Lumos Diagnostics, said: *“We are grateful for the commitment of our existing shareholders in providing this additional capital through the SPP Offer, whose support is pivotal in enabling us to execute on our strategy and maintain momentum at this important inflection point, in difficult market conditions.”*

Whilst we understand that the current share price may not reflect the perceived value in the eyes of the Company or its shareholders, we are now in a position with sufficient capital to significantly power the expansion of FebriDx across over 300,000 locations¹ and 80 million² patients per annum presenting themselves in CLIA Waived settings with acute respiratory infections across the US. Our mission for FebriDx remains: to fundamentally improve patient care and reduce the burden of antimicrobial resistance across the globe, and the current capital position of the company gives us the best possible chance to make this a reality.”

Details of the SPP

The SPP was announced on 27 March 2026. The SPP was offered under a Prospectus dated 9 April 2026 (“Prospectus”) and allowed eligible shareholders to each subscribe for up to A\$30,000 worth of new fully paid ordinary shares in the Company (“SPP Shares”) at A\$0.225 (22.5 cents) per SPP Share.

The Company will issue one (1) free attaching option for every two SPP Shares subscribed for and issued pursuant to the SPP (“SPP Attaching Option”). The SPP Attaching Options will be issued for nil additional consideration, with an exercise price of A\$0.34 (34 cents) per option and an expiry date of 31 December 2027.

Results of the SPP

The Company received valid applications from eligible shareholders (including custodian level applications) for 1,177,770 SPP Shares to raise a total of A\$265,000 (before costs). This total includes applications from eligible Lumos Directors, Sam Lanyon and Catherine Robson, totalling A\$60,000, being 266,666 SPP Shares.

Details of the proposed use of funds raised in the Placement and the SPP can be found in the Company's announcement of the SPP and Placement dated 27 March 2026.

Timing for Issue of SPP Shares and SPP Attaching Options

The Company expects to issue a total of 1,177,770 SPP Shares, 455,544 SPP Attaching Options (588,876 total SPP Attaching Options, less 133,332 options for the two Directors, which will be issued at a later date, when approved by shareholders) and 44,444,422 Placement Options (on the same terms and conditions as the SPP Attaching Options) on 1 May 2026.

The Company intends to hold an Annual General Meeting of shareholders in due course, where it will seek shareholder approval under Listing Rule 10.11 for the issue of 133,332 SPP Attaching Options to the eligible Lumos Directors that participated in the SPP.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About FebriDx

FebriDx® is a rapid, point-of-care test that helps healthcare professionals differentiate between bacterial and non-bacterial respiratory infections after 10 minutes, supporting more informed clinical decision-making and potentially reducing unnecessary antibiotic prescribing.

About Lumos Diagnostics

Lumos Diagnostics is a leading point of care diagnostics company focused on improving the diagnosis and management of acute infectious and inflammatory conditions. Lumos develops and commercialises rapid, clinically actionable tests that are designed to deliver results in minutes and support more targeted treatment decisions at the point of care. The company combines proprietary assay technologies, connected digital reader platforms and scalable manufacturing capabilities to provide end to end solutions for its own Lumos branded products as well as for leading healthcare and life sciences partners worldwide. Lumos generates value through a diversified portfolio of products and partnered programs aimed at addressing significant unmet needs in primary and acute care settings.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not make any representations and provides no warranties

concerning the accuracy of the projections, and disclaims any obligation to update or revise any forward-looking statements/projections based on new information, future events or otherwise except to the extent required by applicable laws.

Not investment advice

This announcement does not provide investment advice or financial product advice. Each recipient of the announcement should make its own enquiries and investigations regarding all information in this announcement including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of the Company and the impact that different future outcomes might have on the Company. Information in this announcement is not intended to be relied upon as advice to investors or potential investors and has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. The Company is not licensed to provide financial product advice in respect of its securities.

Media Contacts:

Haley Chartres – Australia
HACK Director
haley@hck.digital
+61 423 139 163

Investor Contact:

George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598

1. Division of Clinical Laboratory Improvement and Quality Centers for Medicare & Medicaid services, March 2024 (CMS CLIA Database). 2. Precision Business Insights, US Acute Respiratory Infections, 2024.